Error loading player: No playable sources found
Session II: Technical Aspects of Bioassays throughout the Product Lifecycle
Date
April 21, 2021
This product is not available for individual purchase, but it is available as part of the following products:
Session Chairs
Session Speakers
Amgen Inc.
Bristol-Myers Squibb Company
AstraZeneca
MEB-Medical Evaluations Board
Related Products
The Power of Proper System Suitability Tests - A Case Study of cGMP Method Improvement
System suitability assessment is an essential part of bioassay methods. The choice of system suitability parameters and their ranges is critical for ensuring the quality of bioassay results…
Potency Assays for Anti-virus Monoclonal Abs
Viral pathogens can cause wide-spread pandemics (influenza type A, SARS-CoV-2), may have high mortality rates (Ebola virus) and pose enormous health and socioeconomic risks. Certain viruses can also be used as agents for bioterrorism…
Enhancing the Speed of Vaccine Development by Utilizing Fully Automated High throughput Cell Potency Assays
High-throughput analytical assays are one of the key enabling strategies which are needed to support vaccine development…
Bioassay in the Context of the Control Strategy as a Whole
A control strategy, according to ICH Q8, is ‘a planned set of controls, derived from current product and process understanding that ensures process performance and product quality…
